Most recent articles by:

Editorial Team

- Advertisement -

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments in the life sciences industry!...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage trial. The last evaluation of...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular carcinoma (HCC), the combination therapy...

Ipsen and Genfit Receive Accelerated FDA Nod for Liver Disorder Drug

Initially thought of as a potential game-changer for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s drug elafibranor has now been successfully repurposed for treating a...

FDA expert panel backs Eli Lilly’s Alzheimer’s drug donanemab

A panel of experts advising the Food and Drug Administration announced earlier this week, with a unanimous vote, that the benefits of Eli Lilly’s...

Boehringer’s Ingelheim’s Survodutide Shows Liver Fibrosis Improvement

Zealand Pharma has disclosed that Boehringer Ingelheim has published findings from a sub-analysis of a Phase 2 trial using survodutide, showing that after 48...

FDA Considers Monthly Dosing for Alzheimer’s Drug Leqembi

The FDA has accepted Eisai's application for a monthly intravenous maintenance dosing option, as per the announcement. The agency is expected to make a...

FDA Advisory Committee Raises Concerns About Eli Lilly’s Alzheimer’s Drug Donanemab

The FDA’s advisory committee has raised concerns about Eli Lilly’s Alzheimer’s drug donanemab, particularly regarding the risk of brain bleeds in trial patients taking...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm
- Advertisement -